

gofalu am ein gilydd, cydweithio, gwella bob amser caring for each other, working together, always improving

Rydym yn croesawu gohebiaeth yn y Gymraeg ac yn y Saesneg. We welcome correspondence in Welsh or English.

Dyddiad/Date: 13th February 2020

Ein Cyf / Our Ref: 20-A-041



Corporate Services
Headquarters
1 Talbot Gateway
Baglan
Port Talbot, SA12 7BR

I refer to your Freedom of Information Act Request acknowledged by ourselves on 28th January 2020. Your request sought information relating to unlicensed medicines.

Please note that from 1st April 2019 responsibility for providing healthcare services for people in the Bridgend County Borough Council area transferred from Abertawe Bro Morgannwg University Health Board to Cwm Taf Morgannwg University Health Board. In light of this change to ABMU's responsibilities, the organisation's name has changed to Swansea Bay University Health Board. However as this response asks for data prior to 1st April 2019, we have provided the information that ABMU Health Board held which will include Bridgend data.

Please could you supply us with the following information for the period of December 2018 to December 2019 with the purchases of Unlicensed Medicines and UK bespoke special formulations by the Health Board.

Please note that the Health Board has a policy for prescribing and administering unlicensed and off-label medication. If you require a copy of this please let us know.

Could we please have the following information:

 Name and pack size of medicine (generic and propitiatory name if applicable)

Please find attached.

2. The number of packs procured broken down by month as above Please find attached.



Pencadlys BIP Bae Abertawe, Un Porthfa Talbot, Port Talbot, SA12 7BR / Swansea Bay UHB Headquarters, One Talbot Gateway, Port Talbot, SA12 7BR

3. The total cost of the 12 month period for each medicine to the Health Board.

The total spend for all unlicensed medicines during this time period was £2,383,409.92. The information cannot be broken down by medicine as this is considered exempt under Section 43. Section 43 of the Act sets out an exemption for the right to know if release of the information is likely to prejudice the commercial interests of any person (a person may be an individual, a company, the public authority itself or any other legal entity). Section 43 is a qualified exemption. That is, it is subject to the public interest test.

The Health Board accepts that there is a public interest in ensuring openness and transparency and there is an interest in the public being aware of how much money is spent and the benefits derived from that expenditure. However, the Health Board believes that disclosure of information in a manner which fails to protect the interests and relationships arising in a commercial context could have the effect of discouraging companies from dealing with the Health Board because of fears that the disclosure of information could damage them commercially. In turn this could then jeopardise the Health Boards ability to compete fairly and pursue its function to bring forward development in the area and obtain value for money. It was therefore decided that it is not in the publics' interest to disclose this information.

I hope this information is helpful. If you require anything further please contact us at FOIA.Requests@wales.nhs.uk.

Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request please contact me directly at the address below or register your complaint via FOIA.Requests@wales.nhs.uk.

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 029 2067 8400.

Yours sincerely

Pam Wenger

Director of Corporate Governance

P. a. wenger